Risperidone Classification
Risperidone is classified as a second-generation (atypical) antipsychotic. 1
Official Classification
The FDA drug label explicitly describes risperidone as "an atypical antipsychotic belonging to the chemical class of benzisoxazole derivatives" 1. This designation as an atypical (second-generation) antipsychotic is consistent across regulatory documentation and clinical literature 1, 2, 3.
Important Clinical Context
While risperidone is officially classified as second-generation, the most recent international guidelines (2025) emphasize that the first-generation versus second-generation distinction should not guide treatment selection 4. The INTEGRATE guidelines state: "First-generation and second-generation antipsychotics are not a distinct category from either a pharmacological or clinical perspective and this classification should not be used to guide psychotropic choice" 4.
Why This Matters:
Pharmacologically: Second-generation antipsychotics are not a homogeneous class and differ substantially in their receptor profiles, efficacy, and side effects 5
Clinically: The classification was historically based on reduced extrapyramidal side effects, but risperidone can cause dose-dependent extrapyramidal symptoms similar to first-generation agents 3
Treatment decisions: Choice should be based on individual side-effect profiles, efficacy data, and patient-specific factors rather than generation classification 4
Practical Implications
Despite being second-generation, risperidone shares characteristics with both generations: